Vor Bio opts to keep man­u­fac­tur­ing op­er­a­tions in-house for de­vel­op­ing stem cell, CAR-T ther­a­pies

While it is not un­com­mon for a biotech to go down the route of hav­ing the prod­uct man­u­fac­tured by a con­tract or­ga­ni­za­tion, one small biotech is look­ing to keep its card close to its chest.

Vor Bio­phar­ma has start­ed man­u­fac­tur­ing op­er­a­tions at an in-house fa­cil­i­ty at its HQ in Cam­bridge, MA af­ter be­gin­ning con­struc­tion last sum­mer.

Ac­cord­ing to the biotech, the fa­cil­i­ty aims to de­vel­op Vor’s hematopoi­et­ic stem cells (eHSCs) and CAR-T ther­a­pies for pa­tients with blood can­cers. The site will ini­tial­ly man­u­fac­ture a clin­i­cal sup­ply of its can­di­date VCAR33al­lo to sup­port its IND, which is slat­ed to be sub­mit­ted in the first half of next year. It al­so plans to trans­fer the pro­duc­tion of VOR33 to the fa­cil­i­ty. Vor is get­ting to work quick­ly as en­gi­neer­ing runs for VCAR33al­lo has start­ed this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER